Abbreviated name: FTR
Synonyms: BMS-663068 | BMS663068 | compound 35 [PMID: 29271653] | GSK-3684934 | GSK3684934 | Rukobia®
fostemsavir is an approved drug (FDA (2020), EMA (2021))
Compound class:
Synthetic organic
Comment: Fostemsavir is a phosphonooxymethyl prodrug of temsavir (BMS-626529) [4-5]. It is classified as an attachment inhibitor [2]. Temsavir binds to HIV envelope glycoprotein 120 (gp120) and thereby blocks viral attachment to the host CD4 molecule on T-lymphocytes. Naturally ocurring HIV-1 gp120 polymorphisms that could impart resistance to fostemsavir are uncommon [1].
|
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02362503 | Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients | Phase 3 Interventional | ViiV Healthcare | 3 |